KR20240042402A - 경구 이뇨제에 불응성인 부종을 치료하기 위한 피하 제제 및 방법 - Google Patents

경구 이뇨제에 불응성인 부종을 치료하기 위한 피하 제제 및 방법 Download PDF

Info

Publication number
KR20240042402A
KR20240042402A KR1020247000323A KR20247000323A KR20240042402A KR 20240042402 A KR20240042402 A KR 20240042402A KR 1020247000323 A KR1020247000323 A KR 1020247000323A KR 20247000323 A KR20247000323 A KR 20247000323A KR 20240042402 A KR20240042402 A KR 20240042402A
Authority
KR
South Korea
Prior art keywords
bumetanide
pharmaceutical composition
subject
salt
arginine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247000323A
Other languages
English (en)
Korean (ko)
Inventor
발라싱암 라다크리슈난
벤 에스크
웨이 린
앤드루 셴 천
Original Assignee
레스큐 파마슈티컬스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 레스큐 파마슈티컬스 엘엘씨 filed Critical 레스큐 파마슈티컬스 엘엘씨
Publication of KR20240042402A publication Critical patent/KR20240042402A/ko
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020247000323A 2021-06-09 2022-06-09 경구 이뇨제에 불응성인 부종을 치료하기 위한 피하 제제 및 방법 Pending KR20240042402A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163208863P 2021-06-09 2021-06-09
US63/208,863 2021-06-09
PCT/US2022/032862 WO2022261344A1 (en) 2021-06-09 2022-06-09 Subcutaneous formulation and methods for treating edema refractory to oral diuretics

Publications (1)

Publication Number Publication Date
KR20240042402A true KR20240042402A (ko) 2024-04-02

Family

ID=84425561

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247000323A Pending KR20240042402A (ko) 2021-06-09 2022-06-09 경구 이뇨제에 불응성인 부종을 치료하기 위한 피하 제제 및 방법

Country Status (10)

Country Link
US (1) US20240285566A1 (https=)
EP (1) EP4351554A4 (https=)
JP (1) JP2024520788A (https=)
KR (1) KR20240042402A (https=)
CN (1) CN117915905A (https=)
AU (1) AU2022289724A1 (https=)
BR (1) BR112023025880A2 (https=)
CA (1) CA3221710A1 (https=)
IL (1) IL309160A (https=)
WO (1) WO2022261344A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293429A (en) 2019-12-04 2022-07-01 RESQ Pharmaceuticals LLC Methods and preparations for the treatment of edema resistant to oral diuretics

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040105818A1 (en) * 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7906555B2 (en) * 2006-10-26 2011-03-15 Arizona Board Of Regents On Behalf Of The University Of Arizona Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
US20140128469A1 (en) * 2011-05-10 2014-05-08 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
US20210163406A1 (en) * 2018-04-06 2021-06-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs
IL293429A (en) * 2019-12-04 2022-07-01 RESQ Pharmaceuticals LLC Methods and preparations for the treatment of edema resistant to oral diuretics

Also Published As

Publication number Publication date
BR112023025880A2 (pt) 2024-02-27
IL309160A (en) 2024-02-01
CA3221710A1 (en) 2022-12-15
WO2022261344A1 (en) 2022-12-15
EP4351554A4 (en) 2025-05-07
AU2022289724A1 (en) 2024-01-18
JP2024520788A (ja) 2024-05-24
US20240285566A1 (en) 2024-08-29
EP4351554A1 (en) 2024-04-17
CN117915905A (zh) 2024-04-19
WO2022261344A8 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
US12558330B2 (en) Methods and compositions for treating edema refractory to oral diuretics
JP7048576B2 (ja) 酸素化コレステロールサルフェート、並びにポリアルキレングリコール、カルボキシメチルセルロース、及びポリオキシルグリセリドのうち少なくとも1種を含む組成物
TWI815796B (zh) 包含5-膽甾烯-3,25-二醇3-硫酸酯(25hc3s)或其醫藥上可接受之鹽及至少一種環狀寡醣的組成物,以及使用彼等之方法
US20120040970A1 (en) Intranasal delivery system for dantrolene
BR112019014712A2 (pt) Tratamento médio que compreende a administração entérica de edaravona
KR20240042402A (ko) 경구 이뇨제에 불응성인 부종을 치료하기 위한 피하 제제 및 방법
JP2023533129A (ja) 非プロトン性極性溶媒中の安定な持続放出治療組成物およびその製造方法
CN1997383B (zh) 含水母发光蛋白的组合物及使用它的方法
ES2396502T3 (es) Formulaciones para la administración terapéutica de la hormona estimulante de la tiroides (TSH)
AU2022311443A1 (en) Aqueous bumetanide-containing liquid
JPS63303931A (ja) 経鼻投与用成長ホルモン放出活性物質製剤
HK40080175A (en) Methods and compositions for treating edema refractory to oral diuretics
US10201552B2 (en) Method of increasing the bioavailability of an HIV drug
Ichai et al. Sodium disorders
CN120713836A (zh) 一种尼莫地平注射液及其制备方法
HK1208372A1 (en) Liquid formulation
HK1208372B (en) Liquid formulation

Legal Events

Date Code Title Description
PA0105 International application
PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250609

Comment text: Request for Examination of Application